Home›Research›Compare›Foxo4-DRI vs NAD+
Peptide ComparisonFoxo4-DRI vs NAD+
Both are Longevity & Cellular peptides.
Foxo4-DRI
Foxo4-D-Retro-Inverso
Half-life: Unknown
13 providers listed
NAD+
NAD
Half-life: ~1–2 hours (IV); variable (oral)
447 providers listed
NAD+ carries stronger published evidence (RCT, 8 key studies) than Foxo4-DRI (Review, 3); both are research compounds.
Foxo4-DRI
Evidence
Half-life
Unknown
NAD+
Evidence
Half-life
~1–2 hours (IV); variable (oral)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | NAD+ |
| Oral administration option | NAD+ |
| Lower typical price per mg | NAD+ |
| More provider options (13 vs 447) | NAD+ |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Foxo4-DRI
NAD+
Foxo4-DRI
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigat…
Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-…
NAD+
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and…
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Extracellular Lactate Reprograms Mitochondrial Metabolism and NAD(+)/NADH Redox Balance in Blood-Brain Barrie…
+4 more
About Foxo4-DRI
D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"
About NAD+
NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Foxo4-DRI
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
NAD+
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Foxo4-DRI
NAD+
Where to source these peptides
Foxo4-DRI
13 listed
Browse directory →
Providers offeringNAD+
447 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Foxo4-DRI vs NAD+ — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/foxo4-dri/nad-plus